Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-233 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TAK-233 | EXPERIMENTAL | Oral administration |
| Placebo | PLACEBO_COMPARATOR | Oral administration |
| Name | Type | Description |
|---|---|---|
| TAK-233 | DRUG | Oral administration of TAK-233 |
| Placebo | DRUG | Oral admininstration of Placebo |
Inclusion Criteria: 1. Subjects who understand the contents of this clinical trial and who the investigator or sub-investigator consider able to comply with the procedures of the clinical trial 2. Subjects who can sign the informed consent form and can date the form without assistance before starti...
TAK-233 is an investigational small molecule being studied for clinical pharmacology purposes. It is not approved for any specific disease indication. The drug is in early-stage development, with a completed Phase 1 study evaluating its pharmacological properties in healthy subjects.
The molecular target of TAK-233 has not been disclosed. The drug is a small molecule in clinical pharmacology development, and its mechanism of action has not been publicly specified in available clinical trial information.
TAK-233 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Takeda's stock is listed on the New York Stock Exchange under the ticker symbol TAK.
TAK-233 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, and the drug remains investigational. It has not received regulatory approval and is still in the early stages of clinical testing.
TAK-233 has one completed clinical trial, NCT02113020, titled "A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects." This was a randomized, double-blind, placebo-controlled study conducted in Japan with 24 female participants aged 20 years and older.
No alternative names for TAK-233 have been disclosed. The drug is identified solely by its development code TAK-233, and no other names or aliases have been reported in available clinical trial information.